TY - JOUR AU - Mountain, C. F. PY - 1997 DA - 1997// TI - Revisions in the International System for Staging Lung Cancer JO - Chest VL - 111 UR - https://doi.org/10.1378/chest.111.6.1710 DO - 10.1378/chest.111.6.1710 ID - Mountain1997 ER - TY - JOUR AU - O'Byrne, K. J. AU - Dalgleish, A. G. PY - 2001 DA - 2001// TI - Chronic immune activation and inflammation as the cause of malignancy JO - Br J Cancer VL - 85 UR - https://doi.org/10.1054/bjoc.2001.1943 DO - 10.1054/bjoc.2001.1943 ID - O'Byrne2001 ER - TY - JOUR AU - Dalgleish, A. G. AU - O'Byrne, K. PY - 2006 DA - 2006// TI - Inflammation and cancer: the role of the immune response and angiogenesis JO - Cancer Treat Res VL - 130 UR - https://doi.org/10.1007/0-387-26283-0_1 DO - 10.1007/0-387-26283-0_1 ID - Dalgleish2006 ER - TY - JOUR AU - Mastroeni, P. AU - Villarreal-Ramos, B. AU - Hormaeche, C. E. PY - 1993 DA - 1993// TI - Effect of late administration of anti-TNF alpha antibodies on a Salmonella infection in the mouse model JO - Microb Pathog VL - 14 UR - https://doi.org/10.1006/mpat.1993.1046 DO - 10.1006/mpat.1993.1046 ID - Mastroeni1993 ER - TY - JOUR AU - Nakane, A. AU - Minagawa, T. AU - Kato, K. PY - 1988 DA - 1988// TI - Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection JO - Infect Immun VL - 56 ID - Nakane1988 ER - TY - JOUR AU - Bazzoni, F. AU - Beutler, B. PY - 1996 DA - 1996// TI - The tumor necrosis factor ligand and receptor families JO - N Engl J Med VL - 334 UR - https://doi.org/10.1056/NEJM199606273342607 DO - 10.1056/NEJM199606273342607 ID - Bazzoni1996 ER - TY - JOUR AU - Locksley, R. M. AU - Killeen, N. AU - Lenardo, M. J. PY - 2001 DA - 2001// TI - The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology JO - Cell VL - 104 UR - https://doi.org/10.1016/S0092-8674(01)00237-9 DO - 10.1016/S0092-8674(01)00237-9 ID - Locksley2001 ER - TY - JOUR AU - Balkwill, F. PY - 2006 DA - 2006// TI - TNF-alpha in promotion and progression of cancer JO - Cancer Metastasis Rev VL - 25 UR - https://doi.org/10.1007/s10555-006-9005-3 DO - 10.1007/s10555-006-9005-3 ID - Balkwill2006 ER - TY - JOUR AU - Mocellin, S. AU - Rossi, C. R. AU - Pilati, P. AU - Nitti, D. PY - 2005 DA - 2005// TI - Tumor necrosis factor, cancer and anticancer therapy JO - Cytokine Growth Factor Rev VL - 16 UR - https://doi.org/10.1016/j.cytogfr.2004.11.001 DO - 10.1016/j.cytogfr.2004.11.001 ID - Mocellin2005 ER - TY - JOUR AU - Bongartz, T. AU - Sutton, A. J. AU - Sweeting, M. J. AU - Buchan, I. AU - Matteson, E. L. AU - Montori, V. PY - 2006 DA - 2006// TI - Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JO - JAMA VL - 295 UR - https://doi.org/10.1001/jama.295.19.2275 DO - 10.1001/jama.295.19.2275 ID - Bongartz2006 ER - TY - JOUR AU - Furst, D. E. AU - Schiff, M. H. AU - Fleischmann, R. M. AU - Strand, V. AU - Birbara, C. A. AU - Compagnone, D. PY - 2003 DA - 2003// TI - Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) JO - J Rheumatol VL - 30 ID - Furst2003 ER - TY - JOUR AU - Keystone, E. C. AU - Kavanaugh, A. F. AU - Sharp, J. T. AU - Tannenbaum, H. AU - Hua, Y. AU - Teoh, L. S. PY - 2004 DA - 2004// TI - Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial JO - Arthritis Rheum VL - 50 UR - https://doi.org/10.1002/art.20217 DO - 10.1002/art.20217 ID - Keystone2004 ER - TY - JOUR AU - Lipsky, P. E. AU - van der Heijde, D. M. F. M. AU - St Clair, E. W. AU - Furst, D. E. AU - Breedveld, F. C. AU - Kalden, J. R. PY - 2000 DA - 2000// TI - Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis JO - N Engl J Med VL - 343 UR - https://doi.org/10.1056/NEJM200011303432202 DO - 10.1056/NEJM200011303432202 ID - Lipsky2000 ER - TY - JOUR AU - St Clair, E. W. AU - van der Heijde, D. M. AU - Smolen, J. S. AU - Maini, R. N. AU - Bathon, J. M. AU - Emery, P. PY - 2004 DA - 2004// TI - Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial JO - Arthritis Rheum VL - 50 UR - https://doi.org/10.1002/art.20568 DO - 10.1002/art.20568 ID - St Clair2004 ER - TY - JOUR AU - Stone, J. H. AU - Holbrook, J. T. AU - Marriott, M. A. AU - Tibbs, A. K. AU - Sejismundo, L. P. AU - Min, Y. I. PY - 2006 DA - 2006// TI - Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial JO - Arthritis Rheum VL - 54 UR - https://doi.org/10.1002/art.21869 DO - 10.1002/art.21869 ID - Stone2006 ER - TY - JOUR AU - van de Putte, L. B. A. AU - Atkins, C. AU - Malaise, M. AU - Sany, J. AU - Russell, A. S. AU - van Riel, P. L. C. M. PY - 2004 DA - 2004// TI - Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed JO - Ann Rheum Dis VL - 63 UR - https://doi.org/10.1136/ard.2003.013052 DO - 10.1136/ard.2003.013052 ID - van de Putte2004 ER - TY - JOUR AU - Lees, C. W. AU - Ironside, J. AU - Wallace, W. A. AU - Satsangi, J. PY - 2008 DA - 2008// TI - Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMc0800250 DO - 10.1056/NEJMc0800250 ID - Lees2008 ER - TY - JOUR AU - Brown, E. R. AU - Charles, K. A. AU - Hoare, S. A. AU - Rye, R. L. AU - Jodrell, D. I. AU - Aird, R. E. PY - 2008 DA - 2008// TI - A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer JO - Ann Oncol VL - 19 UR - https://doi.org/10.1093/annonc/mdn054 DO - 10.1093/annonc/mdn054 ID - Brown2008 ER - TY - JOUR AU - Du Bois, J. S. AU - Trehu, E. G. AU - Mier, J. W. AU - Shapiro, L. AU - Epstein, M. AU - Klempner, M. PY - 1997 DA - 1997// TI - Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma JO - J Clin Oncol VL - 15 ID - Du Bois1997 ER - TY - JOUR AU - Tsimberidou, A. M. AU - Waddelow, T. AU - Kantarjian, H. M. AU - Albitar, M. AU - Giles, F. J. PY - 2003 DA - 2003// TI - Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment JO - Leuk Res VL - 27 UR - https://doi.org/10.1016/S0145-2126(02)00082-6 DO - 10.1016/S0145-2126(02)00082-6 ID - Tsimberidou2003 ER - TY - JOUR AU - Lejeune, F. J. AU - Ruegg, C. PY - 2006 DA - 2006// TI - Recombinant human tumor necrosis factor: an efficient agent for cancer treatment JO - Bull Cancer VL - 93 ID - Lejeune2006 ER - TY - JOUR AU - Lejeune, F. J. AU - Lienard, D. AU - Matter, M. AU - Ruegg, C. PY - 2006 DA - 2006// TI - Efficiency of recombinant human TNF in human cancer therapy JO - Cancer Immun VL - 6 ID - Lejeune2006 ER - TY - JOUR AU - Boldrini, L. AU - Calcinai, A. AU - Samaritani, E. AU - Pistolesi, F. AU - Mussi, A. AU - Lucchi, M. PY - 2000 DA - 2000// TI - Tumour necrosis factor-[agr] and transforming growth factor-[bgr] are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization JO - Br J Cancer VL - 83 UR - https://doi.org/10.1054/bjoc.2000.1345 DO - 10.1054/bjoc.2000.1345 ID - Boldrini2000 ER - TY - JOUR AU - Tran, T. A. AU - Kallakury, B. V. AU - Ambros, R. A. AU - Ross, J. S. PY - 1998 DA - 1998// TI - Prognostic significance of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma JO - Cancer VL - 83 UR - https://doi.org/3.0.CO;2-Q DO - 3.0.CO;2-Q ID - Tran1998 ER - TY - JOUR AU - Ohri, C. M. AU - Shikotra, A. AU - Green, R. H. AU - Waller, D. A. AU - Bradding, P. PY - 2009 DA - 2009// TI - Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival JO - Eur Respir J VL - 33 UR - https://doi.org/10.1183/09031936.00065708 DO - 10.1183/09031936.00065708 ID - Ohri2009 ER - TY - JOUR AU - Welsh, T. J. AU - Green, R. H. AU - Richardson, D. AU - Waller, D. A. AU - O'Byrne, K. J. AU - Bradding, P. PY - 2005 DA - 2005// TI - Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.01.4910 DO - 10.1200/JCO.2005.01.4910 ID - Welsh2005 ER - TY - JOUR AU - Balkwill, F. PY - 2002 DA - 2002// TI - Tumor necrosis factor or tumor promoting factor? JO - Cytokine & Growth Factor Reviews VL - 13 UR - https://doi.org/10.1016/S1359-6101(01)00020-X DO - 10.1016/S1359-6101(01)00020-X ID - Balkwill2002 ER - TY - JOUR AU - Chen, G. AU - Goeddel, D. V. PY - 2002 DA - 2002// TI - TNF-R1 Signaling: A Beautiful Pathway JO - Science VL - 296 UR - https://doi.org/10.1126/science.1071924 DO - 10.1126/science.1071924 ID - Chen2002 ER - TY - JOUR AU - Szlosarek, P. AU - Charles, K. A. AU - Balkwill, F. R. PY - 2006 DA - 2006// TI - Tumour necrosis factor-alpha as a tumour promoter JO - Eur J Cancer VL - 42 UR - https://doi.org/10.1016/j.ejca.2006.01.012 DO - 10.1016/j.ejca.2006.01.012 ID - Szlosarek2006 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/323/prepub UR - http://www.biomedcentral.com/1471-2407/10/323/prepub ID - ref30 ER -